Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESSION-IPF
2024-511427-34-00Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in idiopathic pulmonary fibrosis (IPF) comparing Esbriet arm with Ofev arm (2 arms). Primary endpoint: Slope of FVC decline over 24 weeks. Started Apr 2024; status: completed.
02
Drugs
pirfenidonenintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2024-511427-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511427-34-00.